Alessandro Del Re


Alessandro Del Re received his MSc in Pharmacy in October 2020 from the Sapienza University of Rome (Italy) with a thesis about the neuropharmacology of the enteric nervous system. In November 2020, he started his PhD in Pharmacology and Toxicology at the Sapienza University of Rome. His research focused on developing genetically engineered probiotics to treat in situ inflammatory conditions and as an orally administrable vaccine platform. He is currently a visiting PhD student in the Beisel lab, where he develops in situ CRISPR-based gene editing tools.